This platform provides single-point-access to an advanced clinical trials package that offers first-into-human testing across a full range of antimicrobial products and treatments – from hygiene and sanitation products, diagnostics, AI wearables and devices, to new therapeutics, and vaccines.
Leveraging the world-leading expertise of Liverpool School of Tropical Medicine (LSTM) and Liverpool University Hospitals NHS Foundation Trust’s MHRA Phase 1 Accredited Clinical Research Unit (CRU), this all-in-one solution covers each stage of the trial journey from study protocol design to downstream analysis. This removes the need for companies to call on the expertise of multiple partners or CROs.
iiCON’s platform provides access to the expert team at the Accelerator Research Clinic (ARC) led by Professor Daniela Ferreira. The state-of-the-art research facility has 18 beds co-located with adjacent laboratories allowing for high clinical and research standards and enabling rapid processing of samples due to clinic and laboratory proximity and the clinic’s expert and experienced team.
Companies undertaking clinical trials also benefit from access to facilities including the largest complement of containment level 3 (CL3) laboratories in the North West and access to a comprehensive BioBank.
For more information or to learn how your business can engage with this platform.
Head of Clinical Sciences Department, Professor of respiratory infection and vaccines immunology at Liverpool School of Tropical Medicine
Daniela is a global leader in Respiratory Infections and Controlled Human Infection Challenge(link is external) with experience in bacterial challenge, co-infection studies, mucosal immunity (nose and lungs) and vaccine testing and immune responses. She leads a Programme of work on respiratory infections and accelerated vaccine development with over £20million from various funders including BMGF, MRC, UKRI, NIHR and several industry partners.